Monday, November 9, 2026

USD/EUR Went Down By Over 1% In The Last 21 Sessions

USD/EUR Went Down By Over 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.56% for the last 21 sessions. At 04:10 EST on Monday, 24 July, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 1.759% up from its 52-week low and 13.9% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.18%, a negative 0.08%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.24% (last week), 0.33% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd: weekly forecast 23rd July - 29th July - 23 July 2023. According to DailyForex on Sunday, 23 July, "The EUR/USD near 1.11000 should be watched early this week to see if the support level can be sustained.", "However, after reaching this apex long-term high early last week, the EUR/USD also mirrored broad Forex conditions and started to produce a rather fast sell-off which escalated as the weekend approached. "
  • Eur/usd steadies above 1.1100 after three-day losing streak, eu/us PMI data, ecb, fed eyed. According to FXStreet on Sunday, 23 July, "Amid these plays, Wall Street closed mixed while the US Treasury bond yields posted a mild weekly gain, which in turn favors US Dollar's further upside and weighs on the EUR/USD price.", "Hence, the latest recovery in the US Dollar appears to lack support from the top-tier US inflation and employment data, which in turn prods the EUR/USD sellers as the key week begins."
  • Eur/usd holds steady above 1.1100 mark, eyes flash euro zone/us pmis for some impetus. According to FXStreet on Monday, 24 July, "This will be followed by the European Central Bank (ECB) meeting on Thursday, which should allow investors to determine the near-term trajectory for the EUR/USD pair. ", "This, in turn, might hold back traders from placing aggressive directional bets and should help limit any meaingful downside for the EUR/USD pair, at least for the time being. "
  • Eur/usd price analysis: edges higher past 1.1100-1090 support zone ahead of eurozone, US PMI. According to FXStreet on Monday, 24 July, "In a case where the EUR/USD remains bearish past 1.1000, an ascending support line from May 31, close to 1.0920, will be the key support before pleasing the pair sellers.", "On the flip side, a clear break of the 1.1090 support could quickly drag the EUR/USD price toward another horizontal support area comprising levels marked since late June, around 1.1010-1000 at the latest."
  • Eur/usd: signs of US disinflation to lift the pair toward 1.15 – ING. According to FXStreet on Monday, 24 July, "Strong signs of US disinflation and bullish steepening of the US yield curve should be a EUR/USD positive. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com